地拉罗司去哪购买呢？

The U.S. Food and Drug Administration (FDA) approved a new indication on January 23, 2013, for the treatment of chronic iron overload in patients 10 years and older with non-transfusion-dependent thalassemia (NTDT). NTDT is a mild form of thalassemia that does not require frequent blood transfusions. But over time, NTDT patients are at risk for iron overload, which can lead to fatal organ damage. The FDA also approved the marketing of FerriScan as an imaging companion diagnostic reagent to deferasirox. The FDA has previously approved FerriScan for the detection of liver iron concentration (LIC), but its use in deferasirox clinical studies is to screen patients for clinical treatment and manage treatment, and its use is limited to imaging and diagnostic reagents necessary for the safe and effective application of deferasirox. 

Deferasirox has been approved for marketing in my country. Patients can purchase deferasirox at large domestic hospitals or pharmacies with a prescription. The only drawback is that the price is relatively high. If patients choose the highly cost-effective Indian deferasirox, in addition to going to India in person, they can also obtain it through domestic professional overseas medical service institutions.

The recommended starting daily dose of deferasirox is 20 mg/kg. For patients who receive monthly transfusions of more than 14 mL/kg of packed red blood cells (i.e., more than 4 units/month in adults) and who need to reduce excess iron exposure, a starting dose of 30 mg/kg/day may be considered. For patients who receive monthly transfusions of less than 7 mL/kg of packed red blood cells (i.e., less than 2 units/month in adults) and who need to maintain body iron balance, a starting dose of 10 mg/kg/day may be considered. In patients who have responded well to deferoxamine therapy, an initial dose of deferasirox equal to one-half the deferoxamine dose may be considered. (For example, a patient receiving deferoxamine 40 mg/kg/day, 5 days per week, or equivalent, may start with deferasirox at 20 mg/kg.) Preparation: Deferasirox should be taken on an empty stomach at least 30 minutes before a meal, once daily, preferably at the same time each day. Tablets should not be chewed or swallowed whole. Deferasirox should not be taken with aluminum-containing antacids, and the dose (mg/kg) needs to be calculated and rounded to the nearest whole tablet. Completely dissolve the tablets in water, apple juice or orange juice (100-200 mL) by stirring until a clear suspension is obtained and drink it. The remaining drug must be added to a small amount of water, apple juice or orange juice and mixed well before taking. Dissolving in carbonated drinks and milk is not recommended as it can cause foaming and slow dispersion. It is used to treat chronic iron overload in patients with beta-thalassemia older than 6 years old due to frequent blood transfusions (monthly administration of concentrated red blood cells ≥7mL/kg); for children under 6 years old and iron overload caused by other transfusion-dependent diseases, it is recommended to use with caution based on the specific conditions of the patient.